Triumvira Immunologics Announces Fast Track Designation for Its First TAC T-Cell Therapeutic Product Candidate: TAC01-CD19
Triumvira Immunologics Announces Fast Track Designation for Its First TAC [...]
Appili Therapeutics Receives FDA and Health Canada Clearance to Begin Clinical Trials on ATI-1501
Appili Therapeutics Receives FDA and Health Canada Clearance to Begin [...]